JP6087289B2 - Ｎａｐｉ２ｂ輸送体に対するヒト化モノクローナル抗体の相補性決定領域に由来する抗腫瘍ペプチド - Google Patents

Ｎａｐｉ２ｂ輸送体に対するヒト化モノクローナル抗体の相補性決定領域に由来する抗腫瘍ペプチド Download PDF

Info

Publication number
JP6087289B2
JP6087289B2 JP2013543901A JP2013543901A JP6087289B2 JP 6087289 B2 JP6087289 B2 JP 6087289B2 JP 2013543901 A JP2013543901 A JP 2013543901A JP 2013543901 A JP2013543901 A JP 2013543901A JP 6087289 B2 JP6087289 B2 JP 6087289B2
Authority
JP
Japan
Prior art keywords
peptide
cancer
tumor
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013543901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510699A5 (https=
JP2014510699A (ja
Inventor
トラバッソス，ルイス，ロドルフォ，ラジャ，ガバグリア
Original Assignee
レセプタ バイオファーマ エス．エー．
レセプタ バイオファーマ エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レセプタ バイオファーマ エス．エー．, レセプタ バイオファーマ エス．エー． filed Critical レセプタ バイオファーマ エス．エー．
Publication of JP2014510699A publication Critical patent/JP2014510699A/ja
Publication of JP2014510699A5 publication Critical patent/JP2014510699A5/ja
Application granted granted Critical
Publication of JP6087289B2 publication Critical patent/JP6087289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/10—Bryophyta (mosses)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2013543901A 2010-12-14 2011-12-14 Ｎａｐｉ２ｂ輸送体に対するヒト化モノクローナル抗体の相補性決定領域に由来する抗腫瘍ペプチド Active JP6087289B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42285610P 2010-12-14 2010-12-14
US61/422,856 2010-12-14
PCT/IB2011/003053 WO2012080822A2 (en) 2010-12-14 2011-12-14 Antitumor peptide derived from a complementarity determining region of a humanized monoclonal antibody to napi2b transporter

Publications (3)

Publication Number Publication Date
JP2014510699A JP2014510699A (ja) 2014-05-01
JP2014510699A5 JP2014510699A5 (https=) 2015-02-05
JP6087289B2 true JP6087289B2 (ja) 2017-03-01

Family

ID=46245158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013543901A Active JP6087289B2 (ja) 2010-12-14 2011-12-14 Ｎａｐｉ２ｂ輸送体に対するヒト化モノクローナル抗体の相補性決定領域に由来する抗腫瘍ペプチド

Country Status (8)

Country Link
US (2) US9193797B2 (https=)
EP (1) EP2654769B1 (https=)
JP (1) JP6087289B2 (https=)
BR (1) BR112013015001B1 (https=)
CO (1) CO6721014A2 (https=)
ES (1) ES2804476T3 (https=)
PT (1) PT2654769T (https=)
WO (1) WO2012080822A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016013258A2 (pt) * 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
CN105491524B (zh) * 2015-12-11 2019-04-26 小米科技有限责任公司 一种确定目标便携设备位置的方法和装置
JP7194180B2 (ja) * 2017-07-01 2022-12-21 レセプタ バイオファーマ エッシ ア ペプチドを使用する方法及び樹状細胞を調節する方法
EP3685166A2 (en) * 2017-09-20 2020-07-29 Mersana Therapeutics, Inc. Compositions and methods for predicting response to napi2b-targeted therapy
WO2022032228A1 (en) 2020-08-07 2022-02-10 The Broad Institute, Inc. Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex
KR102822203B1 (ko) 2020-12-29 2025-06-18 삼성전자주식회사 전력 공급 장치를 이용하여 오디오 출력 장치를 찾는 방법 및 그 전력 공급 장치
CN116514926B (zh) * 2023-06-25 2023-08-29 烟台药物研究所 一种抗肿瘤阳离子两亲肽及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
AU684348B2 (en) * 1994-06-07 1997-12-11 Nihon Medi-Physics Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and adioactive therapeutic agent containing the peptide
US6689753B1 (en) 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
WO2005040219A1 (en) * 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
WO2009097128A1 (en) 2008-01-29 2009-08-06 Ludwig Institute For Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Also Published As

Publication number Publication date
WO2012080822A9 (en) 2016-08-11
BR112013015001A8 (pt) 2018-04-17
CO6721014A2 (es) 2013-07-31
EP2654769A4 (en) 2017-10-25
EP2654769B1 (en) 2020-04-15
US20130315902A1 (en) 2013-11-28
ES2804476T3 (es) 2021-02-08
US9193797B2 (en) 2015-11-24
US20160108132A1 (en) 2016-04-21
BR112013015001B1 (pt) 2021-10-13
US9896512B2 (en) 2018-02-20
PT2654769T (pt) 2020-07-16
BR112013015001A2 (pt) 2017-12-19
EP2654769A2 (en) 2013-10-30
JP2014510699A (ja) 2014-05-01
WO2012080822A2 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
JP6087289B2 (ja) Ｎａｐｉ２ｂ輸送体に対するヒト化モノクローナル抗体の相補性決定領域に由来する抗腫瘍ペプチド
KR102110127B1 (ko) 세포 내재화를 유도하기 위한 ｃｄ20-결합 면역독소 및 이의 사용 방법
EP3210625B1 (en) Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
EP2551347B1 (en) Pharmaceutical composition for preventing or treating cancer
AU2017347822B2 (en) Use of beta-catenin as a biomarker for treating cancers using anti-Dkk-1 antibody
KR20160006697A (ko) 간세포 암종을 검출 및 치료하기 위한 조성물 및 방법
Shoari et al. Anti-angiogenic peptides application in cancer therapy; a review
TW202330620A (zh) 一種靶向ｒｏｒ１的抗體或其抗原結合片段及其應用
US10632179B2 (en) Methods and compositions for treating cancer
EP2665746B1 (en) Antibodies against the s100p protein for the treatment and diagnosis of cancer
EP4491632A1 (en) Ror1-targeted binding molecule and use thereof
EP4537852A1 (en) Her2-gst-sn-38 complex, and pharmaceutical composition comprising same for preventing or treating proliferative diseases
KR101471253B1 (ko) 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
US20190119394A1 (en) Compositions and methods for treating pancreatitis and pain with death receptor agonists
KR20250110754A (ko) 고리형 펩타이드 화합물을 포함하는 암 치료 및/또는 전이 억제용 약학적 조성물
Fetse Discovery and Delivery of Peptide-Based Immune Checkpoint Inhibitors Targeting PD-L1 for Cancer Immunotherapy
WO2026026981A1 (zh) 一种双特异性抗体、抗体偶联药物及其制备方法与应用
HK40092141A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
WO2020162582A1 (en) Methods of treating non-virally-induced cancers
HK40090814A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
CN120590505A (zh) 一种重组补体蛋白及在制备抗白血病药物中的应用
HK40095720A (zh) 抗体分子-药物偶联物及其用途
HK1199835B (en) Therapeutic peptides
HK1215268B (en) Cd20-binding immunotoxins for inducing cellular internalization and methods using same

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160307

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20160309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161013

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170201

R150 Certificate of patent or registration of utility model

Ref document number: 6087289

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250